Literature DB >> 24075927

Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles.

Mark J Ernsting1, Mami Murakami, Aniruddha Roy, Shyh-Dar Li.   

Abstract

Nanoparticle drug delivery to the tumor is impacted by multiple factors: nanoparticles must evade clearance by renal filtration and the reticuloendothelial system, extravasate through the enlarged endothelial gaps in tumors, penetrate through dense stroma in the tumor microenvironment to reach the tumor cells, remain in the tumor tissue for a prolonged period of time, and finally release the active agent to induce pharmacological effect. The physicochemical properties of nanoparticles such as size, shape, surface charge, surface chemistry (PEGylation, ligand conjugation) and composition affect the pharmacokinetics, biodistribution, intratumoral penetration and tumor bioavailability. On the other hand, tumor biology (blood flow, perfusion, permeability, interstitial fluid pressure and stroma content) and patient characteristics (age, gender, tumor type, tumor location, body composition and prior treatments) also have impact on drug delivery by nanoparticles. It is now believed that both nanoparticles and the tumor microenvironment have to be optimized or adjusted for optimal delivery. This review provides a comprehensive summary of how these nanoparticle and biological factors impact nanoparticle delivery to tumors, with discussion on how the tumor microenvironment can be adjusted and how patients can be stratified by imaging methods to receive the maximal benefit of nanomedicine. Perspectives and future directions are also provided.
© 2013.

Entities:  

Keywords:  Biodistribution; Intratumoral penetration; Nanoparticle; Pharmacokinetics; Tumor microenvironment

Mesh:

Substances:

Year:  2013        PMID: 24075927      PMCID: PMC3891171          DOI: 10.1016/j.jconrel.2013.09.013

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  177 in total

1.  Shape effects of filaments versus spherical particles in flow and drug delivery.

Authors:  Yan Geng; Paul Dalhaimer; Shenshen Cai; Richard Tsai; Manorama Tewari; Tamara Minko; Dennis E Discher
Journal:  Nat Nanotechnol       Date:  2007-03-25       Impact factor: 39.213

Review 2.  Stimuli-responsive polymers: biomedical applications and challenges for clinical translation.

Authors:  Allan S Hoffman
Journal:  Adv Drug Deliv Rev       Date:  2012-12-12       Impact factor: 15.470

3.  Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions.

Authors:  Triantafyllos Stylianopoulos; Ming-Zher Poh; Numpon Insin; Moungi G Bawendi; Dai Fukumura; Lance L Munn; Rakesh K Jain
Journal:  Biophys J       Date:  2010-09-08       Impact factor: 4.033

4.  In vivo targeting of B-cell lymphoma with glycan ligands of CD22.

Authors:  Weihsu C Chen; Gladys C Completo; Darren S Sigal; Paul R Crocker; Alan Saven; James C Paulson
Journal:  Blood       Date:  2010-02-24       Impact factor: 22.113

5.  Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding.

Authors:  Nancy Dos Santos; Christine Allen; Anne-Marie Doppen; Malathi Anantha; Kelly A K Cox; Ryan C Gallagher; Goran Karlsson; Katarina Edwards; Gail Kenner; Lacey Samuels; Murray S Webb; Marcel B Bally
Journal:  Biochim Biophys Acta       Date:  2007-01-03

6.  Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.

Authors:  A N Gordon; J T Fleagle; D Guthrie; D E Parkin; M E Gore; A J Lacave
Journal:  J Clin Oncol       Date:  2001-07-15       Impact factor: 44.544

7.  Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles.

Authors:  Suzie H Pun; Frederik Tack; Nathalie C Bellocq; Jianjun Cheng; Brendan H Grubbs; Gregory S Jensen; Mark E Davis; Marcus Brewster; Michel Janicot; Boudewijn Janssens; Wim Floren; Annette Bakker
Journal:  Cancer Biol Ther       Date:  2004-07-09       Impact factor: 4.742

8.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

Authors:  M E R O'Brien; N Wigler; M Inbar; R Rosso; E Grischke; A Santoro; R Catane; D G Kieback; P Tomczak; S P Ackland; F Orlandi; L Mellars; L Alland; C Tendler
Journal:  Ann Oncol       Date:  2004-03       Impact factor: 32.976

9.  Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

Authors:  D W Northfelt; B J Dezube; J A Thommes; B J Miller; M A Fischl; A Friedman-Kien; L D Kaplan; C Du Mond; R D Mamelok; D H Henry
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

10.  Tumor-associated macrophages are predominant carriers of cyclodextrin-based nanoparticles into gliomas.

Authors:  Darya Alizadeh; Leying Zhang; Jungyeon Hwang; Thomas Schluep; Behnam Badie
Journal:  Nanomedicine       Date:  2009-11-05       Impact factor: 5.307

View more
  168 in total

Review 1.  Effect of surface properties on liposomal siRNA delivery.

Authors:  Yuqiong Xia; Jie Tian; Xiaoyuan Chen
Journal:  Biomaterials       Date:  2015-12-02       Impact factor: 12.479

Review 2.  Nanoparticles for Cardiovascular Imaging and Therapeutic Delivery, Part 1: Compositions and Features.

Authors:  John C Stendahl; Albert J Sinusas
Journal:  J Nucl Med       Date:  2015-08-13       Impact factor: 10.057

3.  Improving the distribution of Doxil® in the tumor matrix by depletion of tumor hyaluronan.

Authors:  Aditya G Kohli; Saul Kivimäe; Matthew R Tiffany; Francis C Szoka
Journal:  J Control Release       Date:  2014-05-20       Impact factor: 9.776

4.  Drug-Polymer Interaction, Pharmacokinetics and Antitumor Effect of PEG-PLA/Taxane Derivative TM-2 Micelles for Intravenous Drug Delivery.

Authors:  Qiao Wang; Yi Liu; Chenguang Pu; Hongjuan Zhang; Xinyi Tan; Jingxin Gou; Haibing He; Tian Yin; Yu Zhang; Yanjiao Wang; Xing Tang
Journal:  Pharm Res       Date:  2018-09-13       Impact factor: 4.200

5.  Optimization of Weight Ratio for DSPE-PEG/TPGS Hybrid Micelles to Improve Drug Retention and Tumor Penetration.

Authors:  Ya Jin; Zimei Wu; Caibin Li; Weisai Zhou; John P Shaw; Bruce C Baguley; Jianping Liu; Wenli Zhang
Journal:  Pharm Res       Date:  2018-01-04       Impact factor: 4.200

6.  Effects of the Microparticle Shape on Cellular Uptake.

Authors:  Yuanzu He; Kinam Park
Journal:  Mol Pharm       Date:  2016-03-01       Impact factor: 4.939

7.  Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing.

Authors:  Samantha M Sarett; Thomas A Werfel; Linus Lee; Meredith A Jackson; Kameron V Kilchrist; Dana Brantley-Sieders; Craig L Duvall
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-24       Impact factor: 11.205

8.  Cellular Uptake Mechanism of Paclitaxel Nanocrystals Determined by Confocal Imaging and Kinetic Measurement.

Authors:  Yan Chen; Tonglei Li
Journal:  AAPS J       Date:  2015-06-24       Impact factor: 4.009

9.  Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling.

Authors:  Hong Yang; Shan Yu Fung; Aihua Bao; Qiang Li; Stuart E Turvey
Journal:  J Vis Exp       Date:  2017-07-26       Impact factor: 1.355

Review 10.  Positron emission tomography and nanotechnology: A dynamic duo for cancer theranostics.

Authors:  Shreya Goel; Christopher G England; Feng Chen; Weibo Cai
Journal:  Adv Drug Deliv Rev       Date:  2016-08-09       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.